(18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.
(18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.
复制标题
DOI：
10.15252/emmm.201707809
复制
发表时间：
2017-09
影响因子：
11.1
通讯作者：
Hansson O
中科院分区：
文献类型：
--
作者：
Mattsson N;Schöll M;Strandberg O;Smith R;Palmqvist S;Insel PS;Hägerström D;Ohlsson T;Zetterberg H;Jögi J;Blennow K;Hansson O
为探讨阿尔茨海默病(AD)患者脑脊液总tau(T-tau)和磷酸化tau(P-tau)与18F-AV-1451的关系，我们检测了30例认知健康老年人(15例临床前AD)、14例先证型AD和39例AD痴呆患者。脑脊液T-tau和P-tau高度相关(R=0.92，P<0.001)，但仅与18F-AV-1451的滞留呈中度相关，且主要见于痴呆AD患者。18F-AV-1451与萎缩和认知功能障碍密切相关，而与脑脊液T-tau和P-tau无关。临床前AD患者尽管18F-AV-1451滞留正常，但脑脊液tau升高。然而，并不是所有的痴呆AD患者都表现出脑脊液tau的增加，即使在这个疾病阶段18F-AV-1451的滞留总是增加的。我们得出结论，脑脊液中T-tau和P-tau主要作为“疾病状态”的生物标志物，因为在许多AD患者的所有疾病阶段，在tau聚集体出现之前，它们似乎就已经增加了。相比之下，18F-AV-1451是疾病分期的生物标志物，因为它在疾病的临床阶段会增加，并与脑萎缩和认知能力下降有关。
To elucidate the relationship between cerebrospinal fluid (CSF) total‐tau (T‐tau) and phosphorylated tau (P‐tau) with the tau PET ligand 18F‐AV‐1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T‐tau and P‐tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of 18F‐AV‐1451, and mainly in demented AD patients. 18F‐AV‐1451, but not CSF T‐tau or P‐tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18F‐AV‐1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18F‐AV‐1451 retention was always increased at this disease stage. We conclude that CSF T‐tau and P‐tau mainly behave as biomarkers of “disease state”, since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18F‐AV‐1451 is a biomarker of “disease stage”, since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.